NBTX

Nanobiotix S.A.

• PUBT·07/09 14:03

  WorldQuant discloses net short position in Nanobiotix

• PUBT·07/07 13:41

  Qube Research & Technologies discloses net short position in Nanobiotix

• PUBT·07/06 15:11

  Goldman Sachs cuts Nanobiotix stake below 5% threshold, AMF filing shows

• PUBT·07/01 13:56

  Qube Research & Technologies discloses net short position in Nanobiotix shares

• Seeking Alpha·06/25 09:46

  Nanobiotix: A Highly Speculative Bet On A Potential Radiotherapy Platform

• PUBT·06/16 13:41

  Qube Research & Technologies discloses net short position in Nanobiotix

• Seeking Alpha·06/12 20:58

  Nanobiotix: A Royalty-Backed Physics Platform Hidden Inside A Biotech

• PUBT·06/12 15:14

  Nanobiotix says Goldman Sachs beneficial stake rises to 7.10% of capital, 6.66% voting rights

• PUBT·06/08 13:46

  WorldQuant discloses net short position in Nanobiotix

• TipRanks·06/05 20:27

  Nanobiotix Updates Share Capital and Voting Rights as of May 31, 2026

• Benzinga·06/04 12:51

  Leerink Partners Maintains Outperform on Nanobiotix, Raises Price Target to $46

• TipRanks·06/04 09:10

  Analysts Have Conflicting Sentiments on These Healthcare Companies: Argenx Se (ARGX) and Nanobiotix (NBTX)

• NASDAQ·06/03 13:23

  Nanobiotix Reports Q1 2026 Update; Expects Cash Runway Through 2029

• TipRanks·06/02 22:04

  Nanobiotix Extends Cash Runway to 2029 as Early Lung Cancer Data and Accelerated Phase 3 Plan Advance JNJ-1900

• Benzinga·06/02 20:34

  Nanobiotix Reports Q1 2026 Progress, Highlights 85.7% Response Rate In Phase 2 JNJ-1900 NSCLC Study, FDA Acceptance Of NANORAY-312 Protocol Amendment; Company Believes That The Net Proceeds From The Recent Follow-On Offering, Together With Its Cash And Cash Equivalents Of €42.1 Million As Of March 31, 2026